VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vor Biopharma Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$18.04+0.01 (+0.06%)
Close on Oct 19, 2026
- Market cap
- $979.65M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
83.4%
49M of 59M shares
Institutional holders
102
39 new, 17 sold out
Net institutional buying
9M
In Q2 2026
Insider trades, 12 months
0 buys · 21 sales
Net sold $62.35M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 760,699 | 9.90% | 13G (passive) | Sep 18, 2025 |
| Forbion Growth III Management B.V. | 7,000,000 | 9.99% | 13G (passive) | Sep 18, 2025 |
| FMR LLC | 6,509,996 | 12.00% | 13G (passive) amendment | Jul 31, 2026 |
| VHCP Management EG, LLC | 5,676,370 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Chen Yu | 5,673,078 | 10.50% | 13G (passive) | Mar 30, 2026 |
| Qiming Venture Partners VIII-HC, L.P. | 496,272 | 5.44% | 13G (passive) | Sep 18, 2025 |
| Abigail P. Johnson | 4,932,149 | 9.10% | 13G (passive) | Jun 30, 2026 |
| Verve Capital Limited | 3,410,892 | 6.30% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 3,099,259 | 5.70% | 13G (passive) | Jun 30, 2026 |
| Nimish Shah | 2,216,075 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Rajeev Shah | 12,937,855 | 19.90% | 13D (active) amendment | Jul 16, 2026 |
| RA Capital Management, L.P. | 12,896,519 | 19.90% | 13D (active) amendment | Apr 20, 2026 |
| Reprogrammed Interchange LLC | 1,278,118 | 18.60% | 13D (active) amendment | Oct 14, 2025 |
| Peter Kolchinsky | 12,739,024 | 19.90% | 13D (active) amendment | Apr 14, 2026 |
| Reid Hoffman | 1,204,442 | 17.60% | 13D (active) amendment | Oct 15, 2025 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 10,237,714 | 9.99% | 13D (active) | Dec 18, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VOR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 5,673,078 | 9.59% | $104.44M | – | 2.51% |
| FMR LLC | 4,932,149 | 8.34% | $90.80M | +3,392,479 | 0.00% |
| Fcpm Iii Services B.V. | 4,117,354 | 6.96% | $75.80M | – | 10.10% |
| BlackRock, Inc. | 3,468,107 | 5.86% | $63.85M | +2,673,348 | 0.00% |
| VR Adviser, LLC | 3,041,719 | 5.14% | $56.00M | – | 1.70% |
| State Street Corp | 2,616,336 | 4.42% | $48.17M | +1,497,878 | 0.00% |
| Frazier Life Sciences Management, L.P. | 2,543,939 | 4.30% | $46.83M | – | 1.02% |
| Ra Capital Management, L.P. | 2,402,095 | 4.06% | $44.22M | −3,002,903 | 0.38% |
| Vanguard Capital Management LLC | 2,084,328 | 3.52% | $38.37M | +651,048 | 0.00% |
| Caligan Partners LP | 1,925,066 | 3.25% | $35.44M | – | 1.67% |
| Paradigm Biocapital Advisors LP | 1,750,000 | 2.96% | $32.22M | – | 0.60% |
| Great Point Partners LLC | 1,700,000 | 2.87% | $31.30M | −50,000 | 5.91% |
| Nantahala Capital Management, LLC | 1,690,000 | 2.86% | $31.11M | New | 0.52% |
| Geode Capital Management, LLC | 1,062,469 | 1.80% | $19.56M | +719,896 | 0.00% |
| NEXTBio Capital Management LP | 889,164 | 1.50% | $16.37M | −110,803 | 7.53% |
| ADAR1 Capital Management, LLC | 680,626 | 1.15% | $12.53M | New | 0.57% |
| Logos Global Management LP | 650,000 | 1.10% | $11.97M | −100,000 | 0.52% |
| Rosalind Advisors, Inc. | 648,600 | 1.10% | $11.94M | −51,400 | 4.44% |
| Nan Fung Trinity (Hk) Ltd | 646,550 | 1.09% | $11.90M | New | 1.18% |
| Braidwell LP | 573,104 | 0.97% | $10.55M | +106,330 | 0.39% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 102 | 49M | 83.4% | 39 / 35 | 19 / 17 | 15M | 6M |
| Q1 2026 | 80 | 40M | 68.4% | 35 / 26 | 9 / 9 | 18M | 2M |
| Q4 2025 | 55 | 26M | 43.2% | 29 / 19 | 2 / 10 | 22M | 0M |
| Q3 2025 | 36 | 4M | 6.3% | 36 / 0 | 0 / 1 | 4M | 0M |
| Q2 2025 | 1 | 0M | 0.1% | 0 / 1 | 0 / 0 | 0M | 0M |
| Q1 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of VOR | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,756,293 | 2.97% | $32.33M | 0.30% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,550,885 | 2.62% | $28.55M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 1,270,144 | 2.15% | $26.86M | 0.31% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 1,185,725 | 2.00% | $17.75M | 0.34% | May 31, 2026 |
| iShares Russell 2000 ETF | 951,914 | 1.61% | $17.52M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Growth K6 Fund | 650,678 | 1.10% | $13.76M | 0.30% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 590,012 | 1.00% | $12.48M | 0.17% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 492,147 | 0.83% | $9.06M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 446,413 | 0.75% | $9.44M | 0.03% | Jul 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 402,327 | 0.68% | $8.51M | 0.18% | Jul 31, 2026 |
| Fidelity Small Cap Discovery Fund | 347,860 | 0.59% | $7.36M | 0.32% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 343,954 | 0.58% | $7.27M | 0.33% | Jul 31, 2026 |
| Fidelity Series Small Cap Discovery Fund | 298,000 | 0.50% | $6.30M | 0.32% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 238,381 | 0.40% | $4.39M | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 154,727 | 0.26% | $2.32M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jean-Paul Kress | CEO and Chairman, Director | – | – | Dec 9, 2025 |
| Robert Ang | PRESIDENT AND CEO, Director | 911,318 | 1.54% | May 7, 2025 |
| Jeremy Brett Sokolove | Chief Medical Officer | 27,900 | 0.05% | Apr 9, 2026 |
| Qing Che Zuraw | Chief Development Officer | 937,080 | 1.58% | Dec 9, 2025 |
| Sandesh Mahatme | CFO | 0 | – | Dec 9, 2025 |
| Tirtha Chakraborty | Chief Sci Off & Head Tech Ops | 217,416 | 0.37% | May 7, 2025 |
| Han Wook Choi | Chief Financial Officer | 51,280 | 0.09% | May 2, 2025 |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | 126,625 | 0.21% | Feb 18, 2025 |
| Amy Quinlan | Vice President of Finance | 50,312 | 0.09% | Nov 8, 2024 |
| David Zaccardelli | Director | – | – | Jul 9, 2026 |
| Wouter Joustra | Director | – | – | Jun 12, 2026 |
| Daniella Beckman | Director | – | – | Jun 12, 2026 |
| Michel Detheux | Director | – | – | Jun 12, 2026 |
| Andrew David Levin | Director | – | – | Jun 12, 2026 |
| Alexander Cumbo | Director | – | – | Jun 12, 2026 |
| Erez Kalir | Director | – | – | Jun 12, 2026 |
| Fouad Namouni | Director | – | – | Jun 12, 2026 |
| RA Capital Nexus Fund, L.P. | Director | 1,401,226 | 2.37% | Oct 22, 2025 |
| Sarah Burgess Reed | Director | – | – | Sep 10, 2025 |
| Joshua Resnick | Director | – | – | May 23, 2025 |
| Sven Ante Lundberg | Director | 29,432 | 0.05% | May 23, 2025 |
| David Charles Lubner | Director | – | – | May 23, 2025 |
| Matthew R. Patterson | Director | 41,196 | 0.07% | May 23, 2025 |
| Rajeev M. Shah | 10% owner | 4,501,882 | 7.61% | Aug 26, 2026 |
| Peter Kolchinsky | 10% owner | 4,607,244 | 7.79% | Aug 26, 2026 |
| Ra Capital Management, L.P. | 10% owner | 2,567,245 | 4.34% | Aug 26, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | 1,500 | 0.00% | Aug 26, 2026 |
| TCG Crossover GP II, LLC | 10% owner | – | – | Apr 1, 2026 |
| TCG Crossover Fund II, L.P. | 10% owner | – | – | Apr 1, 2026 |
| TCG Crossover GP III, LLC | 10% owner | – | – | Apr 1, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Capital Healthcare Fund LP RA 10% owner | Aug 24, 2026 | Option exercise | +1,500 | $3.74 | $5.61K | 1,500 |
| Rajeev M. Shah 10% owner | Jul 16, 2026 | Sale | −213 | $19.75 | $4.21K | 4,501,882 |
| Rajeev M. Shah 10% owner | Jul 16, 2026 | Option exercise | +2,100,000 | – | – | 4,502,095 |
| Rajeev M. Shah Director, 10% owner | Apr 22, 2026 | Sale | −165,150 | $15.77 | $2.60M | 2,402,095 |
| Ra Capital Management, L.P. Director, 10% owner | Apr 20, 2026 | Sale | −171,963 | $15.77 | $2.71M | 2,567,245 |
| Ra Capital Management, L.P. Director, 10% owner | Apr 17, 2026 | Sale | −458,411 | $16.28 | $7.46M | 2,739,208 |
| Ra Capital Management, L.P. Director, 10% owner | Apr 15, 2026 | Sale | −53,644 | $16.01 | $858.84K | 3,197,619 |
| Ra Capital Management, L.P. Director, 10% owner | Apr 14, 2026 | Sale | −153,735 | $15.97 | $2.46M | 3,251,263 |
| Ra Capital Management, L.P. Director, 10% owner | Apr 13, 2026 | Sale | −530,610 | $16.15 | $8.57M | 3,404,998 |
| Rajeev M. Shah Director, 10% owner | Apr 10, 2026 | Sale | −828 | $15.75 | $13.04K | 3,935,608 |
| Rajeev M. Shah Director, 10% owner | Apr 9, 2026 | Sale | −135,201 | $16.59 | $2.24M | 3,936,436 |
| Rajeev M. Shah Director, 10% owner | Apr 8, 2026 | Sale | −353,242 | $16.32 | $5.76M | 4,202,499 |
| Rajeev M. Shah Director, 10% owner | Apr 8, 2026 | Sale | −130,862 | $16.91 | $2.21M | 4,071,637 |
| Peter Kolchinsky Director, 10% owner | Apr 6, 2026 | Sale | −537,754 | $16.51 | $8.88M | 4,607,244 |
| Peter Kolchinsky Director, 10% owner | Apr 6, 2026 | Sale | −6,775 | $18.50 | $125.34K | 4,555,741 |
| Peter Kolchinsky Director, 10% owner | Apr 6, 2026 | Sale | −44,728 | $17.31 | $774.24K | 4,562,516 |
| Peter Kolchinsky Director, 10% owner | Apr 2, 2026 | Sale | −258,475 | $18.23 | $4.71M | 5,146,523 |
| Peter Kolchinsky Director, 10% owner | Apr 2, 2026 | Sale | −1,525 | $19.06 | $29.07K | 5,144,998 |
| Ra Capital Management, L.P. Director, 10% owner | Dec 18, 2025 | Award | −4,625,346 | $10.81 | $50.00M | 5,404,998 |
| Sandesh Mahatme CFO | Dec 5, 2025 | Returned to company | −694,137 | – | – | 0 |
| Peter Kolchinsky Director, 10% owner | Oct 30, 2025 | Sale | −24,579 | $25.12 | $617.42K | 779,652 |
| Peter Kolchinsky Director, 10% owner | Oct 29, 2025 | Sale | −251,518 | $25.22 | $6.34M | 804,231 |
| Peter Kolchinsky Director, 10% owner | Oct 28, 2025 | Sale | −87,828 | $27.10 | $2.38M | 1,092,232 |
| Peter Kolchinsky Director, 10% owner | Oct 28, 2025 | Sale | −36,483 | $28.18 | $1.03M | 1,055,749 |
| Ra Capital Management, L.P. Director, 10% owner | Oct 27, 2025 | Sale | −90,941 | $28.12 | $2.56M | 1,180,060 |
| Ra Capital Management, L.P. Director, 10% owner | Oct 24, 2025 | Sale | −53,345 | $28.01 | $1.49M | 1,271,001 |
| Ra Capital Management, L.P. Director, 10% owner | Oct 23, 2025 | Sale | −76,880 | $28.01 | $2.15M | 1,324,346 |
| RA Capital Nexus Fund, L.P. Director | Oct 21, 2025 | Sale | −25,027 | $28.11 | $703.51K | 1,401,226 |
| Interchange LLC Reprogrammed 10% owner | Oct 21, 2025 | Sale | −200 | $30.08 | $6.02K | 1,166,909 |
| RA Capital Nexus Fund, L.P. Director | Oct 20, 2025 | Sale | −6,553 | $30.12 | $197.38K | 1,426,253 |
| RA Capital Nexus Fund, L.P. Director | Oct 20, 2025 | Sale | −1,287 | $30.12 | $38.76K | 0 |
| RA Capital Nexus Fund, L.P. Director | Oct 20, 2025 | Sale | −70,366 | $29.63 | $2.08M | 1,432,806 |
| RA Capital Nexus Fund, L.P. Director | Oct 20, 2025 | Sale | −13,817 | $29.63 | $409.40K | 1,287 |
| Interchange LLC Reprogrammed 10% owner | Oct 20, 2025 | Sale | −11,616 | $30.05 | $349.06K | 1,167,109 |
| Interchange LLC Reprogrammed 10% owner | Oct 17, 2025 | Sale | −24,689 | $30.22 | $746.10K | 1,179,753 |
| Interchange LLC Reprogrammed 10% owner | Oct 17, 2025 | Sale | −1,028 | $31.00 | $31.87K | 1,178,725 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −174,594 | $29.12 | $5.08M | 1,546,621 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −2,492 | $31.00 | $77.25K | 15,104 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −12,691 | $31.00 | $393.42K | 1,503,172 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −6,040 | $30.28 | $182.89K | 17,596 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −30,758 | $30.28 | $931.35K | 1,515,863 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −34,284 | $29.12 | $998.35K | 23,636 |
| Interchange LLC Reprogrammed 10% owner | Oct 16, 2025 | Sale | −2,021 | $30.45 | $61.54K | 1,204,442 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −111,041 | $29.32 | $3.26M | 1,737,061 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −21,804 | $29.32 | $639.29K | 61,032 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −15,826 | $30.36 | $480.48K | 1,721,235 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −3,108 | $30.36 | $94.36K | 57,924 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −20 | $31.35 | $627 | 1,721,215 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −4 | $31.35 | $125 | 57,920 |
| Interchange LLC Reprogrammed 10% owner | Oct 15, 2025 | Sale | −14,851 | $31.05 | $461.12K | 1,263,267 |
| Interchange LLC Reprogrammed 10% owner | Oct 15, 2025 | Sale | −48,910 | $32.05 | $1.57M | 1,214,357 |
| Interchange LLC Reprogrammed 10% owner | Oct 15, 2025 | Sale | −7,894 | $32.77 | $258.69K | 1,206,463 |
| Rajeev M. Shah Director, 10% owner | Oct 15, 2025 | Sale | −234 | $31.17 | $7.29K | 1,848,102 |
| Rajeev M. Shah Director, 10% owner | Oct 15, 2025 | Sale | −46 | $31.17 | $1.43K | 82,836 |
| Rajeev M. Shah Director, 10% owner | Oct 15, 2025 | Sale | −42,699 | $30.55 | $1.30M | 1,848,336 |
| Rajeev M. Shah Director, 10% owner | Oct 15, 2025 | Sale | −8,384 | $30.55 | $256.13K | 82,882 |
| Interchange LLC Reprogrammed 10% owner | Oct 14, 2025 | Sale | −33,668 | $30.32 | $1.02M | 1,278,118 |
| Interchange LLC Reprogrammed 10% owner | Oct 13, 2025 | Sale | −19,672 | $32.36 | $636.59K | 1,314,120 |
| Interchange LLC Reprogrammed 10% owner | Oct 13, 2025 | Sale | −2,334 | $33.09 | $77.23K | 1,311,786 |
| Interchange LLC Reprogrammed 10% owner | Oct 10, 2025 | Sale | −40,983 | $30.97 | $1.27M | 1,333,792 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Capital Healthcare Fund LP RA Director, 10% Stockholder | Oct 20, 2025 | 76,919 | $2.26M | Oct 20, 2025 | Private Financing |
| RA Capital Nexus Fund, L.P. Director, 10% Stockholder | Oct 20, 2025 | 15,104 | $444.51K | Oct 20, 2025 | Private Financing |
| Capital Healthcare Fund LP RA Director, 10% Stockholder | Oct 17, 2025 | 218,043 | $6.32M | Oct 17, 2025 | Private Financing |
| RA Capital Nexus Fund, L.P. Director, 10% Stockholder | Oct 17, 2025 | 42,816 | $1.24M | Oct 17, 2025 | Private Financing |
| RA Capital Nexus Fund, L.P. Director, 10% Stockholder | Oct 16, 2025 | 24,916 | $724.06K | Oct 16, 2025 | Private Financing |
| Capital Healthcare Fund LP RA Director, 10% Stockholder | Oct 16, 2025 | 126,887 | $3.69M | Oct 16, 2025 | Private Financing |
| RA Capital Nexus Fund, L.P. Director, 10% Stockholder | Oct 15, 2025 | 8,430 | $254.75K | Oct 15, 2025 | Private Financing |
| Capital Healthcare Fund LP RA Director, 10% Stockholder | Oct 15, 2025 | 42,933 | $1.30M | Oct 15, 2025 | Private Financing |
| Interchange LLC Reprogrammed 10% Stockholder | Sep 3, 2025 | 23,000,000 | $46.12M | Sep 3, 2025 | Private Placement |
| Ang Robert Officer, Director | Aug 11, 2025 | 18,382 | $36.41K | Aug 11, 2025 | Restricted Stock |
| Ante Lundberg Sven Director | Aug 4, 2025 | 29,432 | $61.59K | Aug 4, 2025 | Exercised Shares |
| Ang Robert Officer, Director | Jul 16, 2025 | 197,937 | $415.39K | Jul 16, 2025 | Exercised Shares |
| Ang Robert Officer, Director | Jul 15, 2025 | 214,135 | $520.59K | Jul 15, 2025 | Exercised Shares |
| Ang Robert Officer, Director | Jul 10, 2025 | 596,885 | $1.39M | Jul 10, 2025 | Restricted Stock |
| Ang Robert Officer, Director | Jul 2, 2025 | 44,936 | $80.44K | Jul 2, 2025 | Restricted Stock |